INT64653

Context Info Confidence 0.44 First Reported 1996 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 17 Total Number 17 Disease Relevance 6.74 Pain Relevance 4.45

extracellular region (CD2) plasma membrane (CD2)

Anatomy Link Frequency T cell 8 effector T lymphocytes 2 macrophages 1 accessory cells 1 leukocyte 1 CD2 (Homo sapiens)

Pain Link Frequency Relevance Heat Neuritis 9 99.52 Inflammation 139 99.08 Arthritis 251 98.88 Acupuncture 280 97.84 psoriasis 362 97.48 Enkephalin 16 97.12 rheumatoid arthritis 80 92.64 Adalimumab 38 90.16 methotrexate 29 89.60 cytokine 149 83.80

Disease Link Frequency Relevance Heat Experimental Autoimmune Neuritis 9 99.52 Disease 113 99.26 INFLAMMATION 136 99.08 Seronegative Spondarthritis 202 98.88 Syndrome 9 97.56 Psoriasis 405 97.48 Apoptosis 18 97.16 Skin Diseases 8 94.04 Rheumatoid Arthritis 80 92.64 Arthritis 57 88.20

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

This recombinant protein binds CD2 on T cells and Fc gamma RIII on accessory cells (e.g., natural killer cells, macrophages), inhibiting T cell activation/proliferation and inducing selective T cell apoptosis.

CD2 Binding (binds) of in accessory cells associated with apoptosis

1) Confidence 0.44 Published 2002 Journal J Pharmacokinet Pharmacodyn Section Abstract Doc Link 12795239 Disease Relevance 0.19 Pain Relevance 0.05

The immediate and marked suppression of ongoing EAN by the mAb lead to the recommendation of anti-CD2 mAbs as candidates for T cell directed immunotherapy of the GBS.

CD2 Binding (recommendation) of in T cell associated with syndrome and neuritis

2) Confidence 0.36 Published 1996 Journal Brain Section Abstract Doc Link 8813272 Disease Relevance 1.10 Pain Relevance 0.58

The peptides are produced after stimulation with the mitogenic monoclonal antibodies anti-CD2.1/2.2 and anti-CD28.

CD2 Binding (stimulation) of

3) Confidence 0.36 Published 1998 Journal J. Neuroimmunol. Section Abstract Doc Link 9600708 Disease Relevance 0 Pain Relevance 0.81

By binding to the CD2 antigen on T cells, alefacept prevents T-cell activation and triggers apoptosis, preferentially targeting memory-effector T cells [3].

CD2 Binding (binding) of in effector T cells associated with apoptosis

4) Confidence 0.36 Published 2006 Journal Arch Dermatol Res Section Body Doc Link PMC1461773 Disease Relevance 0.57 Pain Relevance 0.29

This study supports the notion that T cell activation plays an important role in chronic inflammatory diseases and effective blockade of the LFA-3/CD2 interaction may be useful for treating PsA.

CD2 Binding (interaction) of in T cell associated with inflammation, disease and arthritis

5) Confidence 0.33 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 1.22 Pain Relevance 0.44

The CD2+, CD4+ and CD8+ levels, which are closely associated with activity of T cells, were statistically unchanged except on day 8 after acupuncture (P < 0.05).

CD2 Binding (associated) of in T cells associated with acupuncture

6) Confidence 0.25 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2176150 Disease Relevance 0 Pain Relevance 0.24

Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment.

CD2 Binding (counts) of in T cells associated with acupuncture

7) Confidence 0.25 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2176150 Disease Relevance 0 Pain Relevance 0.13

Blockade of the LFA-3/CD2 interaction, a key co-stimulatory pathway, can inhibit T-cell activation.

CD2 Binding (interaction) of in T-cell

8) Confidence 0.24 Published 2005 Journal J Immune Based Ther Vaccines Section Body Doc Link PMC1208938 Disease Relevance 0.94 Pain Relevance 0.34

With its dual mechanism of action, alefacept blocks the interaction between the leukocyte-function-associated antigen (LFA)-3 and CD2 and thereby impedes the activation and proliferation of T cells.

CD2 Binding (interaction) of in leukocyte

9) Confidence 0.24 Published 2007 Journal Therapeutics and Clinical Risk Management Section Abstract Doc Link PMC2386357 Disease Relevance 0.28 Pain Relevance 0.09

Alefacept binds competitively to the CD2 on the surface of T cells with the LFA-3 portion of the drug and efficiently interferes with LFA-3/CD2 binding and thereby T cell activation (Miller et al 1993), whereas the Fc portion of alefacept engages the immunoglobulin receptor Fc?

CD2 Binding (binds) of in T cell

10) Confidence 0.24 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386357 Disease Relevance 0.49 Pain Relevance 0.17

Alefacept binds competitively to the CD2 on the surface of T cells with the LFA-3 portion of the drug and efficiently interferes with LFA-3/CD2 binding and thereby T cell activation (Miller et al 1993), whereas the Fc portion of alefacept engages the immunoglobulin receptor Fc?

CD2 Binding (binding) of in T cell

11) Confidence 0.24 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2386357 Disease Relevance 0.38 Pain Relevance 0.13

Alefacept is a recombinant protein that binds to CD2 on memory-effector T lymphocytes, inhibiting their activation and reducing the number of these cells.

CD2 Binding (binds) of in effector T lymphocytes

12) Confidence 0.22 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721342 Disease Relevance 0.67 Pain Relevance 0.54

It competitively binds to CD2 cells on T cells to block its activation.

CD2 Binding (binds) of in T cells

13) Confidence 0.16 Published 2008 Journal Indian Journal of Pharmacology Section Body Doc Link PMC2792605 Disease Relevance 0.13 Pain Relevance 0.07

Interaction of CD2 with its ligand, CD58 has been blocked by application of a soluble fully human recombinant fusion protein comprising the first extracellular domain of CD58 and the hinge, CH2 and CH3 sequences of human IgG1 (LFA-3-IgG1; alefacept).

CD2 Binding (Interaction) of in hinge

14) Confidence 0.13 Published 2005 Journal Arthritis Res Ther Section Body Doc Link PMC2833981 Disease Relevance 0.78 Pain Relevance 0.21

Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment.

CD2 Binding (counts) of in macrophages associated with acupuncture

15) Confidence 0.08 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2176150 Disease Relevance 0 Pain Relevance 0.13

Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment.

CD2 Binding (counts) of in B cells associated with acupuncture

16) Confidence 0.08 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2176150 Disease Relevance 0 Pain Relevance 0.13

Cell counts of CD2+, CD4+, CD8+, CD11b+, CD16+, CD19+ and CD56+ were evaluated for variations in T cells, B cells, macrophages and NK cells after acupuncture treatment.

CD2 Binding (counts) of in NK cells associated with acupuncture

17) Confidence 0.08 Published 2007 Journal Evidence-based Complementary and Alternative Medicine : eCAM Section Body Doc Link PMC2176150 Disease Relevance 0 Pain Relevance 0.13

General Comments

This test has worked.